Aclidinium Bromide/Formoterol Fumarate

Phase 3

AstraZeneca PLC (AZN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Chronic Obstructive Pulmonary Disease

View Full Landscape

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease

Clinical Trial

NCT01437397

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/20/2012

Bretaris Genuair

Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

View on EMA

EMA7/20/2012

Eklira Genuair

Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

LinaclotidePhase 3

Irritable Bowel Syndrome With Constipation (IBS-C)

Enfortumab VedotinPhase 3

Muscle Invasive Bladder Cancer